PM launches brain cancer review after swimmer Archie Goodburn's appeal

Review to assess progress since 2018 and speed up access to new treatments, Downing Street says

By LineZotpaper
Published
Updated
Read Time2 min
Sources2 outlets
Prime Minister Andy Burnham has announced a national brain cancer review and a new clinical lead after meeting Scottish swimmer Archie Goodburn, who made a tearful television appeal for more investment in research. The review will look at progress since 2018 and will be followed by a national cancer plan aimed at getting new treatments to patients faster.

Burnham met Goodburn at Downing Street after the 25-year-old athlete, diagnosed with three inoperable brain tumours two years ago, made a tearful plea for more funding. Goodburn, who reached the final of the 50m breaststroke at the 2026 Commonwealth Games in Glasgow, began medical tests after experiencing numbness and seizures while training for the 2024 Olympic trials. He was diagnosed with three large oligodendrogliomas, a rare type of cancer that can affect the brain and spinal cord. He underwent chemotherapy and radiotherapy, but surgery to remove the tumours was found to be impossible.

After the meeting, Burnham announced a new national brain cancer clinical lead and promised a review of brain cancer progress and action to get patients treatment sooner. The review will be led by Professor Anthony Chalmers, chairman of clinical oncology at the University of Glasgow, and will assess what progress has been made in the sector since 2018. It aims to highlight what is still holding progress back.

Downing Street said the review will be followed by a national cancer plan with a view to getting new treatments out of the lab and to patients faster. The prime minister has also asked the Medicines and Healthcare Products Regulatory Agency to conclude its review of the rules for medicines that treat rare conditions sooner, in two years rather than three. Patients, families and charities will help design a drive to get more people onto clinical trials.

Speaking on BBC Breakfast earlier this year, Goodburn described how trials around the world are not being seen in the UK, which he called unfair and unjust. After meeting the prime minister, Goodburn thanked him and said all three of his requests have been promised to some extent, though details still need to be fleshed out.

Burnham described Goodburn as an inspiration to us all and said: "He has spoken passionately about the need for change on brain cancer, and he's right: progress hasn't been good enough, here or anywhere else. Families facing this disease can't afford to wait."

§

Analysis

Why This Matters

  • The review could change how quickly brain cancer patients in the UK gain access to new treatments.
  • The government's request to speed up the MHRA review of rare-disease medicines may affect patients beyond brain cancer.
  • The findings will feed into a national cancer plan, with patients, families and charities involved in designing a push to expand clinical trials.

Background

Brain cancer covers a range of tumours that can be difficult to treat, and outcomes have historically lagged behind some other cancers. The review announced on 14 October 2026 will assess UK progress since 2018 and aims to identify what is still holding the field back. Archie Goodburn's public campaign, including his television appeal and Commonwealth Games performance, brought renewed attention to the issue and led to his meeting with the prime minister.

Key Perspectives

Archie Goodburn: The swimmer has campaigned for faster access to treatments, saying trials available around the world are not reaching UK patients. He welcomed the announcement but said the details still need to be fleshed out. The UK government: Downing Street says the review and the national cancer plan are aimed at getting new treatments out of the lab and to patients faster. It has asked the MHRA to finish its rare-disease medicines review in two years rather than three. Clinicians and researchers: The review, led by Professor Anthony Chalmers and covering progress since 2018, will be watched for whether it leads to concrete changes in funding, regulation and trial access rather than another report that sits on a shelf.

What to Watch

  • The terms of reference for the review led by Professor Anthony Chalmers and who is appointed as the new national brain cancer clinical lead.
  • Whether the MHRA completes its review of rare-disease medicines rules within the two-year timetable requested by the prime minister.
  • Publication of the national cancer plan and any concrete targets for getting more patients onto clinical trials.

Sources

Zotpaper

Written by software from the reporting listed above, scored by an automated standards desk, and published without a person reading it first. If something here is wrong, tell the editor and it will be put right.

How we workSubscribe